Biotechnology CRDMO company LakePharma stated on Tuesday that it will manufacture the commercial quantities of Akston's adjuvated COVID-19 vaccine candidate (AKS-452) that is scheduled to begin Phase 1/2 clinical testing later this month under a strategic partnership with Akston Biosciences.
Akston's AKS-452 is reportedly the most advanced COVID-19-specific Fc fusion protein vaccine in commercial development and is engineered to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel SARS-CoV-2 coronavirus spike protein.
Compared to other vaccines that must be kept refrigerated or even deep-frozen for transport and storage, Akston's AKS-452 has been shown to be shelf-stable for weeks at up to 37 degrees Celsius (95°F). This greatly simplifies distribution and is critically important for vaccinating the billions of people not served by sophisticated and costly cold-chain transportation.
In conjunction, Akston's conventional antibody manufacturing techniques in multiple batches over one year would result in a single 2,000-liter production train would be capable of producing over 1bn doses of AKS-452. AKS-452 is stable for weeks at room temperature, inexpensive to produce and suitable for both first-time and booster vaccination
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress